Patents by Inventor Hafid Ait-Oufella

Hafid Ait-Oufella has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NEUTRALIZING GRANZYME B FOR PROVIDING CARDIOPROTECTION IN A SUBJECT WHO EXPERIENCED A MYOCARDIAL INFARCTION
    Publication number: 20220275105
    Abstract: A method for providing cardioprotection in a subject who experienced a myocardial infarction, including administering a therapeutically effective amount of a Granzyme B inhibitor. Following acute MI in mice, CD8+ T lymphocytes are quickly recruited and activated in ischemic heart tissue, and release Granzyme B, leading to cardiomyocyte apoptosis and deterioration of myocardial function. Antibody-mediated depletion of CD8+ T lymphocytes decreases Granzyme B content and apoptotic within the myocardium and inflammatory response. mAb mediated-CD8 depletion limits myocardial injury and improves heart function. These effects are recapitulated in mice with CD8+ T cell selective Granzyme B deficiency in mice. Granzyme B is produced by other cell types (e.g., NK cells). Global Granzyme B deletion (GzmB-/- mice) decreases apoptotic within the myocardium, reduces local pro-inflammatory signature and ultimately limits infarct size after MI.
    Type: Application
    Filed: July 31, 2020
    Publication date: September 1, 2022
    Applicants: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP), SORBONNE UNIVERSITÉ, UNIVERSITÉ DE PARIS
    Inventors: Hafid AIT-OUFELLA, Nicolas DANCHIN, Icia SANTOS ZAS, Tabassome SIMON
  • Methods and kits for predicting the risk of having a cardiovascular disease or event
    Patent number: 10948498
    Abstract: A cardiovascular event or disease is prevented or treated in a subject by measuring the expression level of soluble Triggering Receptors Expressed on Myeloid cells-1 (sTREM-1) level in a sample from the subject and comparing it to a reference level. Based on this comparison, subjects that are at risk of having or developing a cardiovascular event or disease are identified, and administered a suitable therapy.
    Type: Grant
    Filed: August 8, 2014
    Date of Patent: March 16, 2021
    Assignees: INOTREM, APHP (Assistance Publique-Hôpitaux de Paris), INSERM (Institut National de la Santé et de la Recherche Médicale), Université de Lorraine
    Inventors: Marc Derive, Sebastien Gibot, Hafid Ait-Oufella, Amir Boufenzer, Tabasomme Simon, Nicolas Danchin
  • A B Cell Depleting Agent for the Treatment of Atherosclerosis
    Publication number: 20200376118
    Abstract: The present invention relates to the prevention or treatment of atherosclerosis, in particular to a B cell depleting agent for the prevention or treatment of atherosclerosis.
    Type: Application
    Filed: June 16, 2020
    Publication date: December 3, 2020
    Inventors: Ziad Mallat, Hafid Ait-Oufella, Alain Tedgui, Thomas Tedder
  • Agent capable of depleting CD8 T cells for the treatment of myocardial infarction or acute myocardial infarction
    Patent number: 10556953
    Abstract: The present invention relates to a method for treating MI or AMI in a subject in need thereof comprising a step of administering to said subject a therapeutically effective amount of an agent capable of depleting CD8 T cells. More particularly, this present invention relates to a method for treating acute myocardial infarction by reducing the size of necrosis and limiting 10 the post ischemic left ventricular remodeling.
    Type: Grant
    Filed: October 11, 2016
    Date of Patent: February 11, 2020
    Assignees: INSERM (Institut National de la Santé et de la Recherche Médicale), Université Paris Descartes, Assistance Publique-Hôpitaux de Paris (APHP)
    Inventor: Hafid Ait-Oufella
  • A B Cell Depleting Agent for the Treatment of Atherosclerosis
    Publication number: 20190365890
    Abstract: The present invention relates to the prevention or treatment of atherosclerosis, in particular to a B cell depleting agent for the prevention or treatment of atherosclerosis.
    Type: Application
    Filed: July 9, 2019
    Publication date: December 5, 2019
    Inventors: Ziad Mallat, Hafid Ait-Oufella, Alain Tedgui, Thomas Tedder
  • An Agent Capable of Depleting CD8 T Cells for the Treatment of Myocardial Infarction or Acute Myocardial Infarction
    Publication number: 20180251552
    Abstract: The present invention relates to a method for treating MI or AMI in a subject in need thereof comprising a step of administering to said subject a therapeutically effective amount of an agent capable of depleting CD8 T cells. More particularly, this present invention relates to a method for treating acute myocardial infarction by reducing the size of necrosis and limiting 10 the post ischemic left ventricular remodeling.
    Type: Application
    Filed: October 11, 2016
    Publication date: September 6, 2018
    Applicants: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), Universite Paris Descartes, Assistance Publique-Hopitaux de Paris (APHP)
    Inventor: Hafid AIT-OUFELLA
  • Inhibiting peptides derived from triggering receptor expressed on myeloid cells-1 (TREM-1) TREM-like transcript 1 (TLT-1) for treatment of cardiovascular diseases
    Patent number: 9657081
    Abstract: The present invention relates to a peptide comprising at least 6 consecutive amino acid selected from the amino acid sequence SEQ ID NO: 2 and a function-conservative variant. The invention also relates to a peptide comprising at least 6 consecutive amino acid selected from the amino acid sequence SEQ ID NO: 1 or SEQ ID NO: 2 and a function-conservative variant for use in the treatment of a cardiovascular disease.
    Type: Grant
    Filed: September 9, 2013
    Date of Patent: May 23, 2017
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE DE LORRAINE
    Inventors: Sebastien Gibot, Amir Boufenzer, Hafid Ait-Oufella, Marc Derive
  • METHODS AND KITS FOR PREDICTING THE RISK OF HAVING A CARDIOVASCULAR DISEASE OR EVENT
    Publication number: 20160187352
    Abstract: The present invention relates to a method for diagnosing a cardiovascular event or disease in a subject by measuring sTREM-1 level in a sample.
    Type: Application
    Filed: August 8, 2014
    Publication date: June 30, 2016
    Inventors: Marc DERIVE, Sebastien GIBOT, Hafid AIT-OUFELLA, Amir BOUFENZER, Tabasomme SIMON, Nicolas DANCHIN
  • INHIBITING PEPTIDES DERIVED FROM TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS-1 (TREM-1) TREM-LIKE TRANSCRIPT 1 (TLT-1) AND USES THEREOF
    Publication number: 20150232531
    Abstract: The present invention relates to a peptide comprising at least 6 consecutive amino acid selected from the amino acid sequence SEQ ID NO: 2 and a function-conservative variant. The invention also relates to a peptide comprising at least 6 consecutive amino acid selected from the amino acid sequence SEQ ID NO: 1 or SEQ ID NO: 2 and a function-conservative variant for use in the treatment of a cardiovascular disease.
    Type: Application
    Filed: September 9, 2013
    Publication date: August 20, 2015
    Inventors: Sebastien Gibot, Amir Boufenzer, Hafid Ait-Oufella, Marc Derive
  • Methods for producing a non human model for aortic aneurysm
    Patent number: 8586822
    Abstract: The present invention relates to methods for producing a non human animal model for aortic aneurysm which could provide insight into the diagnosis and treatment of disease. Furthermore, the present invention relates to methods and compositions for the treatment or the prevention of aneurysm in a subject in need thereof.
    Type: Grant
    Filed: September 30, 2008
    Date of Patent: November 19, 2013
    Assignee: INSERM (Institut National de la Sante et de la Recherche Medicale)
    Inventors: Pierre Louis Tharaux, Hafid Ait-Oufella, Alain Tedgui, Ziad Mallat
  • A B Cell Depleting Agent for the Treatment of Atherosclerosis
    Publication number: 20130224215
    Abstract: The present invention relates to the prevention or treatment of atherosclerosis, in particular to a B cell depleting agent for the prevention or treatment of atherosclerosis.
    Type: Application
    Filed: March 8, 2013
    Publication date: August 29, 2013
    Inventors: Ziad Mallat, Hafid Ait-Oufella, Alain Tedgui, Thomas Tedder
  • A B Cell Depleting Agent for the Treatment of Atherosclerosis
    Publication number: 20110275791
    Abstract: The present invention relates to the prevention or treatment of atherosclerosis, in particular to a B cell depleting agent for the prevention or treatment of atherosclerosis.
    Type: Application
    Filed: January 5, 2010
    Publication date: November 10, 2011
    Inventors: Ziad Mallat, Hafid Ait-Oufella, Alain Tedgui, Thomas Tedder
  • Methods for Producing a Non Human Model for Aortic Aneurysm
    Publication number: 20100260726
    Abstract: The present invention relates to methods for producing a non human animal model for aortic aneurysm which could provide insight into the diagnosis and treatment of said disease. Furthermore, the present invention relates to methods and compositions for the treatment or the prevention of aneurysm in a subject in need thereof.
    Type: Application
    Filed: September 30, 2008
    Publication date: October 14, 2010
    Applicant: INSERM
    Inventors: Pierre Louis Tharaux, Hafid Ait-Oufella, Alain Tedgui, Ziad Mallat